BioCentury
ARTICLE | Company News

Ossianix, Lundbeck deal

January 13, 2014 8:00 AM UTC

The companies partnered for two projects using Ossianix's single domain antibody platform based on shark variable new antigen receptor (VNAR) technology. The first project will further develop Ossianix's VNAR antagonists targeting an undisclosed purinergic receptor to treat pain. The compounds are in lead optimization and are expected to start preclinical animal testing this year. The second project is to develop bispecific products comprised of Ossianix's VNAR blood-brain barrier (BBB) targeting module fused to undisclosed mAbs nominated by Lundbeck to treat CNS disorders. Lundbeck will fund the projects and have rights to products developed under the deal. Ossianix will be eligible for development and regulatory milestones. The partners declined to disclose details. ...